

Haematologica
HAEMATOL/2019/241539
Version 4

Comparative analysis of targeted novel therapies in relapsed, refractory
chronic lymphocytic leukaemia

Toby A. Eyre, Nicole Lamanna, Lindsey E. Roeker, Chaitra S. Ujjani,
Brian T. Hill, Paul M. Barr, Erick Lansigan, Bruce D. Cheson, Maryam
Yazdy, John N. Allan, Joanna Rhodes, Stephen J. Schuster, Chadi
Nabhan, Alan Skarbnik, Lori Leslie, Prioty Islam, Katherine Whitaker,
Catherine C. Coombs, Hande H. Tuncer, John M. Pagel, Ryan Jacobs,
Allison M. Winter, Neil Bailey, Andrea Sitlinger, Anna H. Schuh, George
Follows, Christopher P. Fox, Danielle M. Brander, Mazyar Shadman,
and Anthony R. Mato

Disclosures: Conflict-Of-Interest: A.R.M. holds a consultancy role for TG Therapeutics (in addition DSMB), Abbvie, Pharamacyclics, Johnson & Johnson, Regeneron, Astra Zeneca, and Celgene and has received research funding from TG Therapeutics, Abbvie, Pharamacyclics, Johnson & Johnson, Regeneron, Portola, DTRM, and Acerta. L.E.R. has received a travel grant from AbbVie. R.J. has received honoraria from Genentech and AbbVie. B.T.H. has served on advisory boards for and received research funding from Genentech/AbbVie. N.L. participated in advisory boards for AbbVie, AstraZeneca, Genentech, Gilead, Janssen, Juno, Pharamacyclics, is a member of a scientific advisory board for Celgene, and had research funding to the institution from AbbVie, Acerta, AstraZeneca, Beigene, Genentech, Gilead, Juno, Oncternal, TG Therapeutics, and Verastem. D.M.B. serves as consultant for, is a member of the scientific advisory board of, and institution is the site of a PI clinical trial (grant paid to the institution) from AbbVie and Genentech. C.S.U. has received consulting fees from AstraZeneca, Genentech, Gilead, and research support from AbbVie and Pharamacyclics. M.S.Y. received honoraria from Bayer as a speaker. A.P.S. has received research funding from BMS, has received consulting fees from Pharamacyclics, Janssen, AbbVie, Genentech, AstraZeneca, and serves on the Speakers Bureau for Pharamacyclics, Janssen, AbbVie, Genentech, Jazz Pharmaceuticals, Gilead, Kite Seattle, Genetics, Verastem, and Stock ownership for COTA healthcare. J.M.P. has received consulting fees from AbbVie, Pharamacyclics, Genentech, Jazz Pharmaceuticals and serves on advisory boards for Pharamacyclics, AbbVie, and Genentech, speakers bureau for AbbVie, Pharamacyclics, Genentech, Jazz Pharmaceuticals, Gilead Sciences, Verastem, Kite, and Seattle Genetics. C.C.C. has received honoraria from Loxo, Octapharma, H3 Biomedicine, Pharamacyclics and AbbVie and has received consulting fees from AbbVie. P.M.B. has received consulting fees from AbbVie/PCYC, Gilead, Verastem, Genentech. C.N. is employed by Aptitude Health. B.D.C. has received consulting fees from AbbVie, TG Therapeutics, Roche-Genentech, Pharamacyclics, Gilead, Epizyme, Celgene, Morhphosys, Astellas, AstraZeneca, Bayer, Karyopharm, receives research funding to the institution from AbbVie, TG Therapeutics, Roche-Genentech, Pharamacyclics, Gilead, Epizyme, Celgene, Trillium, AstraZeneca. T.A.E. received Honoraria from Roche, Gilead, Abbvie, and Janssen, and holds an advisory board role for Gilead and has received research funding from Gilead, and travelled to conferences for Takeda, Abbvie, and Janssen. A.G is an employee of COTA, Acerta, Genentech, Pharamacyclics/Janssen, and Kite/Gilead; reports receiving other commercial research support and speakers bureau honoraria from, and is a consultant/advisory board member for Takeda, Kite/Gilead, Pharamacyclics/Janssen, Genentech, and Acerta; and holds ownership interest (including patents) in COTA. C.F. reports receiving commercial research grants from Gilead, Abbvie, and Roche; reports receiving other commercial research support from Adienne, reports receiving speakers bureau honoraria from Abbvie, Celgene, Roche, and Janssen; and is a consultant/advisory boardmember for Abbvie, Celgene, Roche, Janssen, Sunesis, Gilead, Takeda, and Atarbio. No potential conflicts of interest were disclosed by the other authors.

Contributions: TE, NL, ARM, LR and MS designed the study. All authors performed data collection and analysis. TE wrote the manuscript and all authors reviewed. ARM supervised the study.